Recombinant Equine IL-5 Protein Summary
Product Specifications
Leu20-Gly134, with a C-terminal 6-His tag
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
2470-EL
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein. |
| Reconstitution | Reconstitute at 50 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
2470-EL/CF
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 100 μg/mL in sterile PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Reconstitution Calculator
Background: IL-5
Interleukin-5 (IL-5) is a secreted glycoprotein that belongs to the alpha -helical group of cytokines (1 ‑ 3). Unlike other family members, it is present as a covalently linked antiparallel dimer (4, 5). Equine IL-5 is synthesized as a 134 amino acid (aa) precursor that contains a 19 aa signal sequence and a 115 aa mature segment. Mature equine IL-5 shares 71%, 66%, 63%, 83%, 88% and 85%, aa sequence identity with human, mouse, rat, canine, feline and porcine IL-5, respectively. IL-5 is primarily produced by CD4+ Th2 cells, but also by activated eosinophils, mast cells, EBV-transformed B cells, Reed‑Sternberg cells in Hodgkin’s disease, and IL‑2‑stimulated invariant natural killer T cells (iNKT) (1 ‑ 3, 6 ‑ 8). IL-5 increases production and mobilization of eosinophils and CD34+ progenitors from the bone marrow and causes maturation of eosinophil precursors outside the bone marrow (1, 6, 9, 10). The receptor for human IL-5, mainly expressed by eosinophils, but also found on basophils and mast cells, consists of a unique ligand-binding subunit (IL-5 R alpha ) and a shared signal‑transducing subunit, beta c (3, 6, 11). IL-5 R alpha first binds IL-5 at low affinity, then associates with preformed beta c dimers, forming a high-affinity receptor (12). IL-5 also binds proteoglycans, potentially enhancing its activity (13). Soluble forms of IL-5 R alpha antagonize IL-5 and can be found in vivo (10, 14). In humans, IL-5 primarily affects cells of the eosinophilic lineage, and promotes their differentiation, maturation, activation, migration and survival, while in mice IL-5 also enhances Ig class switching and release from B1 cells (1 ‑ 3, 9, 10, 15, 16). IL-5 also promotes differentiation of basophils and primes them for histamine and leukotriene release (17).
- Rosenberg, H. F. et al. (2007) J. Allergy Clin. Immunol. 119:1303.
- Elsas, P.X. and M. I. G. Elsas (2007) Curr. Med. Chem. 14:1925.
- Martinez-Moczygemba, M. and D. P. Huston (2003) J. Allergy Clin. Immunol. 112:653.
- Minamitake, Y. et al. (1990) J. Biochem. 107:292.
- McKenzie, A. N. et al. (1991) Mol. Immunol. 28:155.
- Shakoory, B. et al. (2004) J. Interferon Cytokine Res. 24:271.
- Lalani, T. et al. (1999) Ann. Allergy Asthma Immunol. 82:317.
- Sakuishi, K. et al. (2007) J. Immunol. 179:3452.
- Clutterbuck, E. J. et al. (1989) Blood 73:1504.
- Cameron, L. et al. (2000) J. Immunol. 164:1538.
- Tavernier, J. et al. (1991) Cell 66:1175.
- Zaks-Zilberman, M. et al. (2008) J. Biol. Chem. 283:13398.
- Lipscombe, R. et al. (1998) J. Leukocyte Biol. 63:342.
- Tavernier, J. et al. (2000) Blood 95:1600.
- Kopf, M. et al. (1996) Immunity 4:15.
- Horikawa, K. and K. Takatsu (2006) Immunology 118:497.
- Denburg, J. A. et al. (1991) Blood 77:1462.
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Equine IL-5 Protein
There are currently no reviews for this product. Be the first to review Recombinant Equine IL-5 Protein and earn rewards!
Have you used Recombinant Equine IL-5 Protein?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
